Abstract
Introduction
Cysteine aspartyl-specific proteases (caspases) are a family of proteases that cleave substrates at sites next to aspartic acid residues. These proteases are executioners of the cell and also have a role in inflammation and differentiation. There are a total of 14 mammalian caspases thus far identified, 12 of which are human (namely caspases 1-10, 12 and 14) . The caspases are divided into two groups, dependent on their main function. Members, who act in the process of apoptosis, are one group and include caspases 2, 3 and 6-10. The second group are involved in maturation of cytokines and include caspase-1, -4, -5 and -12 [1, 2] . These caspases are present in the cell as inactive zymogens consisting of a prodomain followed by a P20 subunit and P10 subunit, which contain substrate recognition and catalytic domains. Activated caspases cleave a variety of substrates with approximately 400 targets having been identified to date. These include proteins involved in signal transduction (apoptosis regulators, cytokines, serine/threonine kinases), structural proteins (cytoskeletal and nuclear) and proteins involved in regulation of transcription, translation and RNA editing [3, 4] . In contrast to the apoptotic and inflammatory caspases, the precise function of caspase-14 remains undefined. However, a role in keratinocyte differentiation has been determined [5] [6] [7] .
Activation of inflammatory caspases
The inflammatory caspases (1, 4, 5 and 12) are involved in cytokine maturation and consequently the inflammatory response.
Caspase-1 was the first caspase identified and was discovered in 1989 by Black et al. while attempting to determine the protease responsible for the cleavage of interleukin-1␤ (IL-1␤) [25]. Subsequent research, utilizing caspase-1-deficient animal models, demonstrated the requirement of caspase-1 for IL-1␤ maturation [26, 27] Caspase-1 is also involved in the cleavage and activation of interleukin-18 (IL-18) and interleukin-33 (IL-33) [28-30]. A role of caspase-1 in neuronal apoptosis has been proposed. Caspase-1-deficient mice have demonstrated normal developmental cell death [26, 27], however, these models have also shown resistance to cerebral ischaemic injury and also Rip2 and trophic factor withdrawal-mediated neuronal cell death [31-33]. Whether caspase-1 has a direct apoptotic role in these models is unclear, further research is required to determine the true function of caspase-1 in neuronal apoptosis. In contrast, caspase-5 is involved only in IL-
1␤ cleavage [15] . It is believed that caspase-4 and -5 arose from gene duplication due to their sequence homology [1] , although the role of caspase-4 in inflammation needs to be elucidated further. [16] . Asc then recruits caspase-1 through its CARD domain while Caspase-5 recruitment occurs through the CARD domain of Nalp 1 [15] . The assembled Nalp 1 inflammasome is believed to facilitate the dimerization and activation of caspase-1 and -5 [15] [66] . [67, 68] . In 
Activation of inflammatory caspases requires assembly of the inflammasome, a multiprotein complex whose main component is the Nalp proteins, part of the Nod-like receptor (NLR)
family
Initial modifications to peptide-based inhibitors involved the addition of electrophilic groups on the P1 aspartic acid residue such as aldehydes, nitriles or ketones to produce reversible inhibitors. These inhibitors have demonstrated low potency in cell-based systems possibly due to inability to reach necessary concentrations to inhibit sufficient caspase activation
contrast, the addition of chloro, fluoro-, acyloxy, or diazomethyl ketones produces more potent irreversible inhibitors [69] . [75, 76] . [109] [110] [111] [112] [113] .
Role of caspases in disease

Caspases are key mediators of apoptosis and inflammation, the loss or gain of caspase activity/expression is the basis of a number of diseases caused by deregulation of the apoptotic and inflammatory pathways. While important diseases are associated with a lack of caspase activity (e.g. cancer where apoptosis is typically decreased), this review will focus on those diseases and conditions associated with increased caspase activity, as it is in these cases that the role of caspases as therapeutic targets is most clear.
Caspases as targets in conditions associated with increased levels of apoptosis
The irreversible pan-caspase inhibitor IDN6556 has been tested in a rat model of lung transplantation [114] . The [116, 117] [116, 118] . Caspase-1 inhibition may also be beneficial in the treatment of the auto-inflammatory disorder, familial Mediterranean fever which is associated with mutations of the pyrin protein [119, 120] [121] . Pyrin may also bind to caspase-1 directly [122] . [124] .
Inflammatory diseases
Deregulation of the inflammatory response can lead to the development of autoimmune and autoinflammatory disorders. Caspases activate a number of key cytokines required for the inflammatory response. Therefore, caspases represent a target for drugs to prevent induction of this response in inflammatory diseases. Mutations that lead to defects in the components of the inflammasome effect caspase-1 activation and therefore affect the inflammatory response by altering interleukin activation. Mutations in exon 3 of the nalp3 gene have been linked to the auto-inflammatory disorders Muckle-Wells syndrome, familial cold urticaria and chronic infantile neurological cutaneous and articular syndrome. These mutations have been shown to cause hyperresponsiveness to LPS stimulation in peripheral blood mononuclear cells of familial cold urticaria patients and spontaneous secretion of IL-1␤ in monocytic cells
. The reasons for this increase in activity in response to NACHT domain mutations of nalp 3 are unknown. In principle, mutations may enhance inflammasome assembly as the NACHT domain is involved in oligomerization or mutations may reduce the binding of inhibitory proteins to Nalp 3 [37]. The caspase-1 inhibitor VX-765 may have the potential to be used in the treatment of familial cold urticaria and other autoinflammatory diseases. The treatment of peripheral blood mononuclear cells (PBMC) and whole blood from familial cold urticaria patients with VX-765 suppresses LPS-induced IL-1␤ activation
. Mutations in this protein can lead to induction of Asc oligomerization and inflammasome assembly in vitro
Autoimmune disorders occur due to deregulation of the inflammatory response causing self-directed inflammation mediated through the adaptive immune response. Disorders include rheumatoid arthritis and inflammatory bowel disease. Regulation of interleukins through modulation of caspase activity may provide a method to control these disorders. The caspase-1 inhibitor Pralnacasan has been utilized in the treatment of dextran sulfate sodium (DSS)-induced colitis in mice. DSS-induced colitis is a model for human inflammatory bowel disease. Combined treatment with DSS and Pralnacasan showed reduction in inflammatory cells, IL-18 levels in colons and INF-␥ in para-aortal lymph nodes compared with the DSS/placebo group [123]. In a separate study, cytokine expression was investigated in DSS-treated mice. DSS treatment led to an increase in IL-18, TNF-␣, IL-12 and INF-␥ protein levels with Pralnacasan suppressing the increase of IL-18, IL-1␤, TNF-␣ and IFN-␥-inducible protein-10 (IP-10)
Pralnacasan [74] . Upon administration, the ethoxyl group of the compound is hydrolyzed producing the active compound RU36384/VRT-018858 [125] . [126] .
Pralnacasan inhibits LPS-induced IL-1␤ release and S. aureus cowan-induced IL-1␤ and IL-18 release in human PBMC. In a mouse model, Pralnacasan also suppresses IL-1␤ release induced by LPS injection
In [128] . The mechanisms by which caspases contribute to sepsis include the release of cytokines and induction of apoptosis, the degree to which these processes contribute to sepsis is largely unknown.
Role of caspases in sepsis -mediators of apoptosis and inflammation
Sepsis is broadly defined as the systemic inflammatory response to infection. Systemic inflammatory response syndrome (SIRS) is not only caused by infection but a range of processes including ischaemia, multiple trauma, tissue injury and haemorrhagic shock [127]. The mechanism of sepsis is complex and not fully understood. One model proposes that following the SIRS response, the body tries to regain homeostasis by initiating the compensatory antiinflammatory response syndrome (CARS). A combination of both SIRS and CARS responses may also occur and is termed mixed antagonistic response syndrome (MARS)
Role of caspase-1 and -12 in sepsis
The mechanism by which caspase- 1 [130, 131] . Delayed neutrophil apoptosis has been reported to occur during sepsis [132, 133] . Neutrophil numbers are usually tightly regulated in vivo by the induction of apoptosis approximately 5 hrs after maturation [134] 
mediates its response in sepsis is not fully understood but is believed to involve the activation of interleukins through the inflammasome. IL-18 activation stimulates the inflammatory response by INF-␥ production and T-cell polarization and may act as a predictive factor for lethal sepsis [129]. Additionally, caspase-1 activation of IL-1␤ leads to the upregulation of pre-B cell colony-enhancing factor in neutrophils inhibiting apoptosis of these cells
Role of apoptotic caspases in sepsis
The apoptotic caspases also play a part in the development of sepsis. Increased lymphocyte apoptosis may occur in sepsis contributing to the symptoms of CARS. Reduced levels of B-, CD4 T-and dendritic cells have been reported in septic patients and also in animal models of sepsis [133, 136, 137] . Caspase-2, -3, -6 and -9 have been implicated in lymphocyte apoptosis [138] and prevention of lymphocyte apoptosis by caspase inhibitors improves survival in sepsis models [137, 139] 
. Lymphocyte apoptosis not only contribute to CARS by reducing the number of Band T-cells, but also the uptake of apoptotic cells can lead to macrophage and dendritic cell non-responsiveness known as
anergy [140] .
The utilization of caspase therapeutics may prove problematic in the case of sepsis due to lack of knowledge regarding the complex nature of sepsis development and progression and also the diverse roles that caspases may perform in this condition.
Challenges facing the development of caspase therapeutics
In the development of a safe and effective caspase therapeutics, a number of criteria, such as drug specificity and selectivity, must be considered. This section highlights some of the key questions, which must be addressed in the development of caspase therapeutics.
Firstly, an understanding of the contribution of apoptosis to cell death in the condition to be treated is essential, along with knowledge of the caspases implicated and the therapeutic window for treatment. As [146, 147] . The possibility of inducing autophagic cell death upon caspase inhibition must be considered during the development of beneficial caspase therapeutics.
Role of caspases in non-apoptotic and non-inflammatory processes
While caspases play critical roles in apoptosis and inflammation, it has emerged that some caspases contribute to other important biological processes including differentiation and proliferation. These additional roles are as yet poorly understood but must be considered when assessing the risk of adverse effects following treatment with caspases inhibitors. [5] [6] [7] .
Role of caspases in differentiation and cell fusion
A similar process of denucleation occurs in lens fiber cells. Caspases have been implicated in this process due to the observation of PARP cleavage and inhibition of denucleation performed with the pan caspase inhibitor Z-VAD-fmk in differentiating cells. However, the caspases implicated are unknown, both caspase-3 and -9 are putative mediators of denucleation [149] [150] [151] . Caspases have also been implicated in the differentiation of erythrocytes and dendritic cells [152] [153] [154] [155] .
Caspases are involved in the process of cell fusion. [157] .
Role of caspases in cell proliferation
Caspases are implicated in T-cell proliferation due to the suppression of growth upon treatment with caspase inhibitors [158, 159] . Caspase-8 may be involved in this process as the caspase-8 inhibitor c-FLIP1 has been shown to modulate T-cell proliferation [160] 
